Somewhat Negative News Coverage Somewhat Unlikely to Impact RXi Pharmaceuticals (NASDAQ:RXII) Stock Price

Press coverage about RXi Pharmaceuticals (NASDAQ:RXII) has been trending somewhat negative recently, according to Accern. The research group ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. RXi Pharmaceuticals earned a news impact score of -0.09 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.6606899845869 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several research firms have weighed in on RXII. HC Wainwright set a $3.00 price objective on RXi Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 2nd. ValuEngine raised RXi Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 2nd.

Shares of RXi Pharmaceuticals traded up $0.12, hitting $1.64, during trading hours on Friday, Marketbeat.com reports. 61,997 shares of the company’s stock traded hands, compared to its average volume of 805,657. RXi Pharmaceuticals has a 12-month low of $1.29 and a 12-month high of $7.70.

RXi Pharmaceuticals (NASDAQ:RXII) last released its earnings results on Thursday, May 10th. The biotechnology company reported ($0.90) earnings per share (EPS) for the quarter. The firm had revenue of $0.02 million for the quarter. sell-side analysts predict that RXi Pharmaceuticals will post -2.32 EPS for the current year.

RXi Pharmaceuticals Company Profile

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye.

Recommended Story: What is the NASDAQ Stock Market?

Insider Buying and Selling by Quarter for RXi Pharmaceuticals (NASDAQ:RXII)

Receive News & Ratings for RXi Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply